← Back to Search


Radiation Therapy for Neuroblastoma

Led By David Kozono, MD, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights


This trial aims to understand how radiation treats cancer while avoiding side effects, by collecting data & biospecimens before, during & after radiation & annotating them w/clinical, biological & other features.

Who is the study for?
This trial is for children and young adults with specific types of brain tumors or high-risk neuroblastoma. Participants must meet certain age, health, and diagnostic criteria, have stable vital functions, and not be pregnant or breastfeeding. They should also be enrolled in one of the specified clinical trials related to their condition.Check my eligibility
What is being tested?
The MCT aims to collect detailed biological data from patients undergoing radiation therapy for tumor treatment. It involves external beam radiotherapy and a radioactive drug called 131I-MIBG to understand how these treatments work against tumors while assessing potential side effects.See study design
What are the potential side effects?
Potential side effects may include damage to healthy tissues due to radiation exposure, thyroid issues from radioactive iodine (131I-MIBG), fatigue, nausea, blood count changes leading to increased infection risk or bleeding problems.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Event-free survival by DNA damage response
Event-free survival by tumor DNA alterations
Event-free survival by tumor heterogeneity
Secondary outcome measures
Proportion of patients with serious adverse events by DNA damage response

Trial Design

2Treatment groups
Experimental Treatment
Group I: NeuroblastomaExperimental Treatment1 Intervention
Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B
Group II: Diffuse Midline GliomaExperimental Treatment1 Intervention
Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B
First Studied
Drug Approval Stage
How many patients have taken this drug
External beam radiotherapy
Completed Phase 2

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Neuroblastoma include chemotherapy, radiation therapy, and molecularly targeted therapies. Chemotherapy, using agents like cisplatin and etoposide, works by damaging the DNA of rapidly dividing cancer cells, leading to cell death. Radiation therapy targets the tumor with high-energy rays to destroy cancer cells while sparing surrounding healthy tissue. Molecularly targeted therapies, such as those inhibiting specific pathways like the sonic hedgehog pathway, aim to block the growth and spread of cancer cells by interfering with specific molecular targets involved in tumor growth. Understanding these mechanisms is crucial for Neuroblastoma patients as it allows for the development of more effective and less toxic treatments, improving survival rates and quality of life.
Understanding regulation of cell growth in childhood brain tumors.

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,959,354 Total Patients Enrolled
205 Trials studying Neuroblastoma
53,637 Patients Enrolled for Neuroblastoma
Brigham and Women's HospitalLead Sponsor
1,628 Previous Clinical Trials
11,474,593 Total Patients Enrolled
Dana-Farber Cancer InstituteOTHER
1,085 Previous Clinical Trials
341,733 Total Patients Enrolled
10 Trials studying Neuroblastoma
3,926 Patients Enrolled for Neuroblastoma
~31 spots leftby Aug 2028